INTRODUCTION
============

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is an enigma in urology although it is a common disorder \[[@B1]\]. Because it is diagnosed only on the basis of symptoms, principally pain or discomfort in the pelvic region \[[@B2]\], it may not be treated adequately. Although pain is the most severe and commonly reported symptom in patients with CP/CPPS, many patients have lower urinary tract symptoms (LUTS), especially storage symptoms, such as frequency and urgency \[[@B3]-[@B6]\].

Among the most commonly used treatments for CP/CPPS are antibiotics, α-blockers, and anti-inflammatory drugs. Anticholinergic agents are used to treat frequency and urgency; however, the role of anticholinergics in the management of CP/CPPS is unknown, and there are few references on the topic \[[@B7]\].

The aim of this study was to evaluate the prevalence of LUTS and the efficacy of solifenacin in a prospective, randomized, single-blinded, multi-centered clinical trial of young and middle-aged CP/CPPS patients.

PATIENTS AND METHODS
====================

This study was performed under the Institutional Review Board approval of each clinical trial center, and written informed consent was given by all patients. At four Korean centers, a total of 96 patients with CP/CPPS were randomly assigned into group 1 (n=49; ciprofloxacin 1,000 mg once daily) or group 2 (n=47; ciprofloxacin 1,000 mg and solifenacin 5 mg once daily) with single blinded randomization method. All patients had a urine analysis, urine culture, expressed prostatic secretions examination, prostate-specific antigen (PSA) measurement, uroflowmetry, and postvoid residual volume (PVR) measurement. The International Prostate Symptom Score (IPSS), the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and the International Index of Erectile Function-5 (IIEF-5) were used to grade the patients\' symptoms and the quality of life (QoL) impact at the starting point (baseline) and at 4 and 8 weeks into the study.

Patients aged 20 to 49 years were included to exclude the LUTS of benign prostatic hyperplasia (BPH). Other inclusion criteria were patients diagnosed with CP/CPPS (NIH-CPSI category IIIa and IIIb) and with pelvic pain for 3 or more months, negative urine culture and expressed prostatic secretion results, PVR of 100 mL or less, maximum urinary flow rate (Qmax) of 15 mL/sec or greater, a total NIH-CPSI score of 8 or greater, and an NIH-CPSI pain score of 4 or greater at baseline. Exclusion criteria included a history of previous prostate surgery, 5α-reductase inhibitor use for 3 or more months, anticholinergic use within 6 months of baseline, PSA level of 4.0 ng/mL or more, prostatic cancer, urethral stricture, diabetes mellitus, neurogenic bladder and hypersensitivity to ciprofloxacin (1,000 mg) or solifenacin.

Statistical analysis was performed by repeated-measures analysis of variance with SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA), and P\<0.05 was considered to indicate significance.

RESULTS
=======

There was no significant difference between group 1 and 2 at the baseline when the age, duration of disease, PVR, Qmax, scores on the IPSS, NIH-CPSI or IIEF-5 were compared. Among those patients, 67.4% demonstrated LUTS (IPSS ≥ 8). In NIH-CPSI score, there were statistically significant differences between group I and II in total (12.1±7.4 vs. 10.8±5.4, P=0.01), pain (5.3±3.6 vs. 13.9±5.0, P=0.04) and urinary domain scores (1.9±1.6 vs. 2.1±1.8, P=0.01) at 8 weeks of treatment. Whereas after 8weeks of treatment, there was no statistical differences in QoL scores between group I and II: 5.1±3.0 vs. 5.1±1.8, P=0.13 ([Table 1](#T1){ref-type="table"}). Statistically significant differences were found in the IPSS total score and storage domain score between group I and II at 8 weeks of treatment. IPSS total score was 5.3±5.5 and 7.2±4.7 (P=0.04), and the storage was 2.0±2.2 and 3.2±2.3 (P=0.01), respectively. Also, these scores were significantly decreased compared to the baseline scores. Even though, voiding scores (3.4±3.7 vs. 4.0±3.2, P=0.22) and QoL scores (1.7±1.2 vs. 2.4±1.4, P=0.38) were decreased from the mean scores during 8 weeks of treatment, there was no statistical differences ([Table 2](#T2){ref-type="table"}). The total score of the IIEF-5 was increased without any significant statistical differences ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

CP/CPPS is a common disorder in men, and the syndrome is diagnosed only on the basis of symptoms, principally pain or discomfort in the pelvic region. Because the pathophysiology of the disease has not been established, antimicrobial agents are frequently used. However a patient who does not respond to antibiotics might need additional treatments, such as nonsteroidal anti-inflammatory drugs, alpha-blocking agents, or other therapies for symptomatic relief \[[@B1], [@B8]\].

Dmochowski and Gomelsky \[[@B9]\] suggested that CP/CPPS was another condition with prominent LUTS. The condition is typically accompanied by pain with ejaculation or in the perineal area. Because there is no gold standard diagnostic test for CP/CPPS and because its etiology is largely unknown, this entity remains a diagnosis of exclusion. As with BPH, the symptoms of CP/CPPS can be present during the storage phase, can be present during the voiding phase, or can occur postmicturition \[[@B9]\].

A recent study showed that because CP/CPPS is an important multifactorial problem that affects men of all ages and demographic subgroups, patients with CP/CPPS receive many empirical therapies. The three most common treatments prescribed by physicians are antimicrobial agents, anti-inflammatory medicines, and alpha-adrenergic receptor antagonists \[[@B10]\]. Many theories exist on the efficacy of the medicines prescribed; however, there remains a lack of scientific evidence to prove their efficacy \[[@B11]\]. Therefore, there is a need for a long-term, randomized, controlled study to evaluate the efficacy of treatment, especially because controversy concerning the efficacy and mechanism of action of alpha-blockers in the treatment of CP/CPPS.

Furthermore, many studies have investigated the efficacy of antimicrobial agents and alpha-adrenergic receptor antagonists, but there have been few studies of the efficacy of other medicines used in empirical treatment, such as plant extracts, zinc, antidepressants, anti-anxiety medications, 5-alpha reductase inhibitors, narcotics, analgesics, anticholinergics, or antispasmodics.

In recent reports, the primary symptoms of CP/CPPS were pelvic pain and frequent urination \[[@B4],[@B6],[@B12]\].

However, many physicians have used anticholinergics empirically for treatment, and there are only introductions to treatment with anticholinergics in some of the guidelines \[[@B7]\].

In this study, to evaluate the prevalence of LUTS and the efficacy of anticholinergics, we used the IPSS, NIH-CPSI, and IIEF-5 to grade the symptoms and QoL impact. In our study, only young and middle-aged patients were included to exclude the LUTS of BPH because BPH patients have a higher prevalence of LUTS than do healthy men and a higher prevalence of sex-related symptoms \[[@B13]\]. In the present study, we found statistically significant differences between the two groups in the total score, pain domain, and urinary domain of the NIH-CPSI and the total score and storage symptom score of the IPSS. In a recent study investigating treatment of CP/CPPS with alfuzosin, alfuzosin improved only the voiding symptom score determined via the IPSS and not the storage symptoms assessed by the IPSS or any of the domains in the NIH-CPSI \[[@B14]\], Such finding provide the basis for believing that combined therapy with alpha-blockers and anticholinergics may show synergistic effects in the management of CP/CPPS. The IPSS assessment appears to be a good indicator for follow-up in the management of CP/CPPS, especially in patients with severe LUTS \[[@B12]\]. Solifenacin improved the pain associated with CP/CPPS in our study, but we think that this was probably because some patients with interstitial cystitis were included in the study.

Our data suggests that anticholinergics are effective in the management of CP/CPPS, especially for the treatment of storage symptoms. However, because the number of patients was small and the period of the clinical trial was short, more randomized, controlled, long-term and large-scale clinical trials are needed.

In our study, the scores between the two groups were compared. However, to prove the effective of anticholinergics in CP/CPPS, absolute decreased values between two groups should be considered during the study.

In conclusion, many CP/CPPS patients had LUTS. Solifenacin demonstrated efficancy in CP/CPPS in improving the NIH-CPSI and the IPSS total score and storage score. Storage factors improved significantly, as determined via the NIH-CPSI and IPSS in the solifenacin treatment group.
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Comparison of the NIH-CPSI results in the pre-treatment and post-treatment groups

![](inj-15-172-i001)

1.8Values are presented as mean±SD.

NIH-CPSI, National Institutes of Health chronic prostatitis symptom index; QoL, quality of life.

Group 1: antibiotics alone. Group 2: antibiotics and solifenacin (5 mg).

^a)^Indicates a significant difference from group 1 (P\<0.05) by repeated measure analysis of variance.
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Comparison of the IPSS results in the pre-treatment and post-treatment groups
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1.4Values are presented as mean±SD.

IPSS, International Prostate Symptom Score; QoL, quality of life.

Group 1: antibiotics alone. Group 2: antibiotics and solifenacin (5 mg).

^a)^Indicates a significant difference from group 1 (P\<0.05) by repeated measure analysis of variance.
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Comparison of the IIEF results in the pre-treatment and post-treatment groups
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5.9Values are presented as mean±SD.

IIEF-5, International Index of Erectile Function-5.

Group 1: antibiotics alone. Group 2: antibiotics and solifenacin (5 mg).
